VERTEX PHARMACEUTICALS INCORPORATED
Ownership & governance
Executives 5Directors 10Avg age 61Avg tenure 7.4y
RK
Reshma Kewalramani
Chief Executive Officer
Age 53Since 2020-03-31Profile →
+14
Executives5
RK
Reshma Kewalramani→
Chief Executive Officer
Age 53Since 2020-03-31
CW
Charles Wagner
Director of Finance/CFO
Age 58Since 2019-04-09
MB
Mark Bunnage
Chief Tech/Sci/R&D Officer
—Since 2021-06-30
EA
Edward Atkinson
Chief Tech/Sci/R&D Officer
Age 60Since 2023-08-28
AU
Agam Upadhyay
Chief Tech/Sci/R&D Officer
—Since 2025-06-30
Board of directors10
BS
Bruce Sachs→
Director/Board Member
Age 66Since 1997-12-31
JL
Jeffrey Leiden→
Chairman
Age 70Since 2012-04-30
SB
Sangeeta Bhatia→
Director/Board Member
Age 57Since 2015-06-17
AG
Alan Garber→
Director/Board Member
Age 70Since 2017-06-07
RK
Reshma Kewalramani→
Director/Board Member
Age 53Since 2020-02-29
LC
Lloyd Carney→
Director/Board Member
Age 64Since 2019-02-20
NT
Nia Tatsis→
Director/Board Member
Age 56Since 2025-10-09
DM
Diana McKenzie→
Director/Board Member
Age 61Since 2020-06-02
Shareholders4
| Name | Stake | Shares |
|---|---|---|
| Capital Research & Management Co. (World Investors) | 9.995 % | 25,368,124 |
| Capital Research & Management Co. (Global Investors) | 8.324 % | 21,125,964 |
| BlackRock Advisors LLC | 7.02 % | 17,818,088 |
| Vanguard Capital Management LLC | 6.506 % | 16,512,810 |
Catalog · 2026-07-09
Proxy officers26
| Name | Role | Since | Shares |
|---|---|---|---|
| Jeffrey Leiden | Chairman | 2012-04-30 | - |
| Alan Garber | Director or executive officer | 2017-01-01 | 37,626 |
| Alan Garber | Director/Board Member | 2017-06-07 | - |
| Amit Sachdev | Director or executive officer | — | 48,490 |
| Bruce I. Sachs | Director or executive officer | 1998-01-01 | 94,530 |
| Bruce Sachs | Director/Board Member | 1997-12-31 | - |
| Carmen Bozic | Director or executive officer | — | 25,497 |
| Charles F. Wagner, Jr | Director or executive officer | — | 27,723 |
Proxy · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 571.43Range 350–667Analysts 28
350Mean 571.43667
- Strong buy 6
- Buy 20
- Hold 5
- Sell 1
Broker actions40 of 554
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | 576 | 2026-10-08 |
| UBS | Maintained | Buy | 615 | 2026-09-28 |
| Truist Securities | Maintained | Buy | 565 | 2026-08-05 |
| Barclays | Maintained | Overweight | 617 | 2026-08-05 |
| TD Cowen | Maintained | Buy | 550 | 2026-08-04 |
| Cantor Fitzgerald | Maintained | Overweight | 595 | 2026-08-04 |
| Canaccord Genuity | Maintained | Hold | 442 | 2026-08-04 |
| UBS | Maintained | Buy | 585 | 2026-07-13 |
| Truist Securities | Maintained | Buy | 560 | 2026-07-13 |
| RBC Capital | Maintained | Outperform | 570 | 2026-07-07 |
| Baird | Maintained | Underperform | 350 | 2026-07-07 |
| Barclays | Maintained | Overweight | 615 | 2026-05-06 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.